Multivariate analysis by a Cox’s proportional hazard model for hazard ratios of overall mortality and treatment discontinuation in patients received cetuximab as salvage treatment for advanced KRAS wild type (exon 2 non-mutant) CRC. This evidence concerns the gene KRAS and colorectal carcinoma.